Life Insurance
Consensus Index

AI Consensus Fit Review

Banner Life Insurance Fit Review for Type 2 Diabetes

Banner Life is a good fit for an adult with reasonably stable Type 2 diabetes who wants medically underwritten term coverage, but it is not a guaranteed approval and not a diabetes-specialist program.

Research: 2026-09-227 usable platform responsesRead the methodology ↗

Share

Answer Capsule

Banner Life is a good fit for an adult with reasonably stable Type 2 diabetes who wants medically underwritten term coverage, but it is not a guaranteed approval and not a diabetes-specialist program. Six of seven platforms named Banner Life during the ranking stage, and it finished third overall with an average listed rank of 1.33. The strongest reason to consider it is OPTerm's combination of 10- to 40-year level terms, conversion flexibility, and published underwriting guidance that treats well-controlled diabetes more favorably than many competitors. The main limitation is that Banner does not publish a Type 2 diabetes rate table, approval probability, or guaranteed treatment of insulin use, so final pricing and eligibility remain case-specific.

Research Snapshot

FieldFinding
Platform mentions in ranking stage6 of 7 platforms (anthropic, google, grok, kimi, openai, perplexity)
Share of included platform responses85.7%
Average listed rank1.33
Best listed rank1
Relevant product/model/planOPTerm term life insurance, including 10-, 15-, 20-, 25-, 30-, 35-, and 40-year level-premium terms
Overall use-case fitGood, with meaningful underwriting uncertainty
Research date2026-09-22

Why Banner Life Qualified for This Study

Questions This Section Answers

  • Is Banner Life a good choice for life insurance for Type 2 diabetes?
  • How often did AI platforms rank Banner Life for Type 2 diabetes applicants?

Banner Life qualified because it was named by six of the seven platforms during ranking discovery and placed first on four of them (anthropic, grok, kimi, openai), second on two (google, perplexity), and was not named by deepseek. That produced an average listed rank of 1.33 and a final rank of third in the study. The platform-level fit ratings were not unanimous: anthropic, google, grok, and kimi rated Banner a strong fit; openai and perplexity rated it good; deepseek rated it uncertain.

The qualification rests on a specific product, not a general reputation. Every platform that named Banner pointed to OPTerm term life insurance, with most describing 10- to 40-year level terms [1]. Independent reviewers repeatedly describe Banner as a carrier that checks first for diabetic applicants [4], and one analysis called Banner the most affordable carrier for people with diabetes [6]. Those are platform-reported and publisher-reported claims, not independently verified outcomes.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for Type 2 Diabetes

Questions This Section Answers

  • Which Banner Life plan should a buyer with Type 2 diabetes choose, OPTerm or something else?
  • Does Banner Life OPTerm offer term lengths long enough for a mortgage or income-replacement need?

OPTerm is the relevant product. It is a level-premium term policy with seven durations — 10, 15, 20, 25, 30, 35, and 40 years — and level death benefits during the initial period [7]. Coverage is described as starting at $100,000 and reaching up to $10 million, with issue ages to 75 [9]. The 35- and 40-year options matter because most competitors top out at 30 years [11].

Two underwriting pathways exist. Accelerated underwriting may produce an instant or exam-free decision for eligible applicants, and Banner states that accelerated and traditional term policies are priced at the same rates when the applicant qualifies for the accelerated process [12]. Traditional underwriting remains available and may require a paramedical exam, labs, prescription history, or an attending physician statement [14]. Banner's own materials state that an APS may be required for diabetes, which means accelerated underwriting should not be assumed to eliminate records review [14].

Conversion is the other structural feature. OPTerm can be converted to permanent coverage during the guaranteed level-premium period or until attained age 70, whichever comes first, with a shorter conversion window for policies issued at age 66 or older [15]. Conversion is available without new underwriting, but the permanent product available through conversion is a universal life policy, not whole life [16].

What the AI Platforms Agreed About

Questions This Section Answers

  • What do AI platforms agree on about Banner Life for well-controlled Type 2 diabetes?
  • Does Banner Life offer better rate classes than competitors for controlled diabetes?

The clearest agreement is that Banner is favorable for well-controlled Type 2 diabetes and unfavorable for poorly controlled diabetes. Five platforms (anthropic, google, grok, kimi, perplexity) independently reported that applicants with stable A1C, no significant complications, and consistent medical follow-up can reach Standard or Standard Plus rate classes rather than table ratings [17]. Several described Banner's approach as holistic — evaluating the whole applicant rather than penalizing a single condition [22].

Platforms also agreed on the adverse end of the spectrum. Banner's February 2026 field guide lists A1C above 10 and significant diabetes complications as situations requiring decline or postponement [24]. Google's platform additionally reported postponement where diabetes was diagnosed within the last six months, where there has been no physician follow-up in 24 months, or for applicants under 40 with uncontrolled blood sugar [27].

A third area of agreement is product structure: long term options, conversion availability, and a terminal-illness accelerated death benefit included with OPTerm [28]. Platforms also agreed that Banner does not sell standalone permanent coverage [30].

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

  • Is Banner Life's accelerated underwriting actually available to applicants with Type 2 diabetes?
  • How much does Banner Life cost per month for a 40-year-old with Type 2 diabetes?

Accelerated underwriting eligibility for diabetic applicants is the sharpest conflict. Kimi reported that Banner excludes people with diabetes from lab-free accelerated approval and that a medical exam is generally required [32]. Grok reported that lab-free options exist but are generally unavailable or limited for diabetes applicants [34]. OpenAI and perplexity reported that accelerated underwriting exists with eligibility depending on age, health history, product type, and requested coverage, without confirming diabetes-specific treatment [35]. Banner's public materials do not resolve this.

Coverage limits for accelerated underwriting also conflict. Banner's field guide states up to $5,000,000 for ages 20-60 and up to $500,000 for ages 61-70 with an APS required [37]. One independent review states the APPcelerate program approves up to $1,000,000 without a medical exam for ages 20 to 50 [39]. Another cites up to $5 million [40]. The discrepancy likely reflects program tiers or updates, but it is unresolved in the supplied evidence.

Term length availability also conflicts. Banner's own term page describes 10-, 20-, and 30-year terms, while third-party descriptions mention terms up to 40 years [41]. The company's OPTerm product materials and multiple platforms support the 10-40 year range [43].

Pricing is uncertain rather than disputed. No platform verified a diabetes-specific premium. The commonly cited figure — roughly $42 per month for women and $54 for men at age 40 for $500,000 of 20-year coverage — comes from a single independent analysis and is repeated across platforms [45]. Banner's own advertised "$8 a month" example applies to a 20-year-old female nonsmoker in excellent health buying $100,000 of 10-year coverage and is not representative of a diabetic applicant [50].

Use-Case-Specific Features and Capabilities

Questions This Section Answers

  • What underwriting factors does Banner Life evaluate for Type 2 diabetes?
  • Does Banner Life blend or stack ratings for diabetes plus another condition like elevated BMI?

Banner's underwriting review covers medical screening, medical history, medications, family history, financial and public records, and other risk information [52]. For diabetes specifically, the factors platforms identified are A1C and glucose control, age at diagnosis, diabetes duration, oral medication versus insulin use, complications, weight, blood pressure, and follow-up consistency [53].

Two features distinguish Banner in the platform findings. First, a non-stacking or "blended" approach to co-morbidities: rather than stacking separate table ratings for diabetes and elevated BMI, Banner blends them, which can produce a better outcome than a competitor's lower nominal table rating [56]. Second, a reported baseline practice of pricing rated policies from the Standard Plus Non-Tobacco class, which one reviewer says often lands lower than a competitor's Table 4 [58].

Reported thresholds vary by source and should be treated as directional. One directory reported Banner targets A1C below 7.5 with no complications and stable weight as the best-case scenario [54]. Another reported applicants with A1C between 6.0% and 7.0%, no insulin use, and no complications often qualify for standard pricing [60]. Grok reported Standard Plus possible for onset age 50+ with A1C under 8 in some scenarios [61]. Google reported that even a 0.1% A1C increase beyond preferred limits can trigger a Table 2 rating [62]. These are not Banner-published cutoffs.

Riders include an accelerated death benefit for qualifying terminal illness, a term rider, a children's rider, and waiver of premium, subject to eligibility, state availability, and additional cost [63]. Banner does not offer chronic illness or critical illness riders, and its accelerated death benefit applies to terminal diagnoses rather than chronic conditions [64].

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

  • What fees does Banner Life charge on OPTerm beyond the premium?
  • What happens to Banner Life OPTerm premiums after the initial level term ends?

Banner's OPTerm product specifications list a $90 annual policy fee for Banner Life products, with an $80 fee for William Penn in New York [66]. Payment-mode factors are listed as 0.51 semiannual, 0.26 quarterly, and 0.085 monthly EFT [66]. Optional riders may add cost or carry separate eligibility limits [68].

Premiums are level only during the selected initial term. After that period, coverage is renewable annually to age 95 but premiums increase each year and coverage may be reduced [66]. Two-year contestability and suicide provisions apply, and coverage begins only after approval, outstanding requirements, policy delivery or acceptance, and receipt of the first premium [66]. Google's platform reported a 30-day free-look period allowing cancellation for a full premium refund [69].

No diabetes-specific fee was identified in the sources reviewed, and Banner generally arranges medical examinations at company expense [66]. A quoted price is not a final offer; final health class and premium follow medical and underwriting review [66]. Rate quotes for identical coverage can vary 40-50% between carriers, according to one agency source [70].

Best Suited For

Questions This Section Answers

  • Who is Banner Life OPTerm best suited for among Type 2 diabetes applicants?
  • Is Banner Life a good fit for a buyer who wants a 35- or 40-year term?

Banner Life OPTerm is best suited to applicants with stable Type 2 diabetes, regular medical follow-up, an acceptable recent A1C, and no significant complications who want competitively priced term coverage [71]. It fits buyers who need 10 to 40 years of coverage for income replacement, mortgage protection, or family obligations, and who value the possibility of accelerated processing while being able to supply full medical records if required [73].

It also fits applicants who want conversion flexibility without new underwriting, and those who want to lock in rates while diabetes control is strong [71]. Buyers who want a single insurer offering both an accelerated lane and a traditional fully underwritten lane are also a reasonable match [75].

Probably Not Best Suited For

Questions This Section Answers

  • Who should not choose Banner Life for life insurance with Type 2 diabetes?
  • Does Banner Life decline applicants with transplant history or cardiomyopathy?

Banner is probably not the best fit for applicants with A1C above 10, significant diabetes complications, or incomplete medical follow-up [76]. It is also a poor match for buyers seeking guaranteed-issue or simplified-issue coverage without meaningful health underwriting, and for buyers who need permanent lifetime coverage rather than temporary term protection [78].

Applicants with transplant history or cardiomyopathy are automatic declines with Banner [80]. Buyers with combination impairments such as diabetes plus heart disease are also flagged as cases where another carrier may be better [82]. New York residents cannot obtain a Banner Life policy; William Penn Life of New York is the issuing company there [84]. Buyers who want a dedicated mobile app for policy management should note Banner does not offer one [86].

When Another Option May Be Better

Questions This Section Answers

  • What is a better alternative to Banner Life for a Type 2 diabetes buyer who needs permanent coverage?
  • When should a Type 2 diabetes buyer choose a guaranteed-issue product instead of Banner Life?

Another carrier may be better when the buyer needs permanent coverage with cash value, since Banner offers term and conversion-only universal life rather than standalone whole life or universal life [87]. A diabetes-focused independent broker can obtain informal underwriting opinions from multiple carriers before a formal application, which is the practical route when A1C, insulin use, duration, or complications sit near a threshold [89].

Guaranteed-issue or simplified-issue coverage may be more appropriate when the buyer has severe complications or cannot qualify for medically underwritten term coverage, though such products commonly involve lower limits, higher premiums, exclusions, or waiting provisions [89]. Buyers who want a diabetes-specific wellness program with premium savings may prefer John Hancock's Aspire program, which one analysis describes as offering virtual health coaching and up to 25% premium savings for eligible policyholders [91]. Buyers with higher A1C or insulin dependence may find Prudential more lenient per one directory source [93].

Questions to Verify Before Buying

Questions This Section Answers

  • What should a buyer confirm with Banner Life before signing an OPTerm contract?
  • How can a buyer confirm whether Banner Life will require a medical exam for diabetes?

Confirm whether Type 2 diabetes qualifies for accelerated underwriting or whether Banner will require a paramedical exam, labs, prescription report, and attending physician statement [94]. Ask how the latest and historical A1C, glucose control, diabetes duration, medication or insulin use, weight, blood pressure, kidney function, cardiovascular history, neuropathy, and retinopathy will affect the proposed rate class [96].

Request an informal underwriting class and estimated premium before submitting a formal application, and confirm whether the quote includes the $90 annual policy fee and all selected riders [98]. Ask what premiums and death-benefit changes apply after the initial level-premium period, and what the maximum conversion age and deadline are for the applicant's issue age and selected term [98]. Confirm state availability, the exact state-specific policy form, exclusions, contestability and suicide provisions, reinstatement rules, and accelerated-death-benefit effects [99]. Finally, ask what records or health improvements would support reconsideration if the application is postponed or declined [98].

Final AI Consensus Verdict

Banner Life is a good, not automatic, fit for an adult with reasonably stable Type 2 diabetes seeking term coverage. Six of seven platforms named it, four ranked it first, and the platform-level fit ratings ranged from strong to uncertain. The strongest evidence-backed case for Banner is structural: OPTerm offers 10- to 40-year level terms, conversion without new underwriting, and a published underwriting guide that treats well-controlled diabetes more favorably than many competitors while flagging A1C above 10 and significant complications as adverse [100].

The limitations are equally clear. Banner publishes no Type 2 diabetes rate table, no approval probability, and no guaranteed treatment of insulin use, diabetes duration, or specific complications [102]. Accelerated underwriting eligibility for diabetic applicants is disputed across platforms. The commonly cited $42-$54 monthly figure is a single publisher's analysis, not a Banner quote. Buyers should treat Banner as one candidate among several, obtain informal underwriting opinions from multiple carriers, and confirm diabetes-specific acceptance rules in writing before relying on any published marketing.

How This Review Was Produced

This review was generated from seven AI platform responses collected for the query "An adult with Type 2 diabetes wants life insurance and is otherwise in reasonably stable health." Each platform evaluated Banner Life's fit for that use case and supplied citations. The study date is 2026-09-22. Platform mentions in the ranking stage count only platforms that named Banner Life during ranking discovery; all seven platforms evaluated fit, but deepseek did not name Banner in its ranking output. Citations are platform-reported evidence and were not independently verified by the writer stage. Company-owned sources are labeled as owned; independent sources are labeled as independent.

Methodology Limitations

Platform-reported research dates differ from the authoritative run date: deepseek reported 2026-02-14 while the remaining platforms reported 2026-09-22. Platform-reported dates are provenance metadata and do not independently prove freshness. Deepseek ran with search disabled, so its findings are model-reported rather than retrieved. The supplied URLs were collected from platform responses and were not independently validated. Banner's public materials do not disclose a diabetes-specific rate table, exact A1C cutoffs for all underwriting classes, or how each combination of insulin use, complications, weight, and follow-up affects final offers. No independent comparative study or regulator-published diabetes-specific outcome data was located in the sources reviewed. The available evidence is largely company-produced product and underwriting material plus publisher reviews; it is not independent evidence of comparative market performance. Agreement among AI platforms does not prove product quality. One official-site retrieval returned only a headline and Trustpilot reference and was not used as a verified fact source.

See the broader Life Insurance for Type 2 Diabetes consensus index for comparisons across qualified options.

From the index

Compare the adjacent findings before forming a view.

Sources

Company-Owned Sources

Independent Sources

Other Sources

  • Life Insurance | Legal & General America: https://www.lgamerica.com
  • Additional AI research evidence103 records
    1. AI research evidence record openai:c6
    2. AI research evidence record anthropic:physicians-opterm-terms
    3. AI research evidence record perplexity:c5
    4. AI research evidence record anthropic:ogletree-banner-check-first
    5. AI research evidence record anthropic:keyperson-banner-type-2
    6. AI research evidence record anthropic:moneygeek-banner-most-affordable-diabetics
    7. AI research evidence record openai:c6
    8. AI research evidence record anthropic:30-1
    9. AI research evidence record anthropic:physicians-opterm-terms
    10. AI research evidence record anthropic:banner-official-opterm-coverage
    11. AI research evidence record anthropic:30-2
    12. AI research evidence record openai:c4
    13. AI research evidence record perplexity:c3
    14. AI research evidence record openai:c3
    15. AI research evidence record openai:c7
    16. AI research evidence record anthropic:usnews-banner-no-standalone-ul
    17. AI research evidence record anthropic:banner-keyperson-standard-plus
    18. AI research evidence record google:keyperson_diabetes
    19. AI research evidence record grok:7
    20. AI research evidence record kimi:keypersoninsurance
    21. AI research evidence record perplexity:c11
    22. AI research evidence record anthropic:banner-phi-underwriting-holistic
    23. AI research evidence record anthropic:13-2
    24. AI research evidence record openai:c2
    25. AI research evidence record perplexity:c1
    26. AI research evidence record google:banner_field_underwriting_guide
    27. AI research evidence record google:banner_beyond_term_guide
    28. AI research evidence record perplexity:c9
    29. AI research evidence record perplexity:c14
    30. AI research evidence record anthropic:usnews-banner-no-standalone-ul
    31. AI research evidence record anthropic:keyperson-banner-term-only
    32. AI research evidence record kimi:planwithphil
    33. AI research evidence record kimi:marketwatch
    34. AI research evidence record grok:4
    35. AI research evidence record openai:c3
    36. AI research evidence record perplexity:c15
    37. AI research evidence record anthropic:banner-official-appcelerate-coverage
    38. AI research evidence record perplexity:c5
    39. AI research evidence record anthropic:physicians-appcelerate-ages-20-50
    40. AI research evidence record anthropic:moneygeek-appcelerate-1m
    41. AI research evidence record deepseek:c1
    42. AI research evidence record deepseek:c2
    43. AI research evidence record openai:c6
    44. AI research evidence record anthropic:30-1
    45. AI research evidence record anthropic:moneygeek-banner-most-affordable-diabetics
    46. AI research evidence record anthropic:39-7
    47. AI research evidence record grok:1
    48. AI research evidence record kimi:moneygeek
    49. AI research evidence record google:moneygeek_diabetics
    50. AI research evidence record openai:c9
    51. AI research evidence record perplexity:c7
    52. AI research evidence record openai:c1
    53. AI research evidence record anthropic:riskquoter-diabetes-underwriting-details
    54. AI research evidence record anthropic:riskquoter-a1c-target
    55. AI research evidence record kimi:keypersoninsurance
    56. AI research evidence record google:banner_impaired_toolkit
    57. AI research evidence record google:banner_opt_rates_review
    58. AI research evidence record anthropic:banner-ogletree-standard-plus-approach
    59. AI research evidence record anthropic:31-6
    60. AI research evidence record anthropic:affordable-life-type2-standard
    61. AI research evidence record grok:7
    62. AI research evidence record google:keyperson_diabetes
    63. AI research evidence record openai:c10
    64. AI research evidence record anthropic:24-3
    65. AI research evidence record anthropic:24-4
    66. AI research evidence record openai:c7
    67. AI research evidence record anthropic:moneygeek-banner-naic-rating
    68. AI research evidence record openai:c10
    69. AI research evidence record google:banner_opt_rates_review
    70. AI research evidence record anthropic:6-5
    71. AI research evidence record openai:c7
    72. AI research evidence record anthropic:riskquoter-type2-well-controlled-rates
    73. AI research evidence record openai:c3
    74. AI research evidence record anthropic:30-2
    75. AI research evidence record deepseek:c1
    76. AI research evidence record openai:c2
    77. AI research evidence record perplexity:c1
    78. AI research evidence record openai:c7
    79. AI research evidence record anthropic:usnews-banner-no-standalone-ul
    80. AI research evidence record anthropic:keyperson-banner-declines
    81. AI research evidence record anthropic:40-1
    82. AI research evidence record anthropic:14-6
    83. AI research evidence record anthropic:14-7
    84. AI research evidence record openai:c8
    85. AI research evidence record deepseek:c3
    86. AI research evidence record anthropic:44-7
    87. AI research evidence record anthropic:usnews-banner-no-standalone-ul
    88. AI research evidence record anthropic:keyperson-banner-term-only
    89. AI research evidence record openai:c7
    90. AI research evidence record anthropic:riskquoter-banner-prudential-lincoln
    91. AI research evidence record anthropic:39-2
    92. AI research evidence record kimi:johnhancock
    93. AI research evidence record kimi:lifeinsureguide
    94. AI research evidence record openai:c3
    95. AI research evidence record perplexity:c15
    96. AI research evidence record anthropic:riskquoter-diabetes-underwriting-details
    97. AI research evidence record kimi:keypersoninsurance
    98. AI research evidence record openai:c7
    99. AI research evidence record openai:c8
    100. AI research evidence record openai:c6
    101. AI research evidence record openai:c7
    102. AI research evidence record openai:c2
    103. AI research evidence record perplexity:c15

Verify this research

Check when the research was run, which platforms were included, and what supports the findings.

Study date
September 22, 2026
Platforms analyzed
7
Source records
54
Ranking mentions
6 of 7
Platform share
86%
Final consensus rank
#3

Behind the findings

Platforms in this study

  • ChatGPT
  • Claude
  • DeepSeek
  • Grok
  • Perplexity
  • Kimi
  • Gemini

Source records

27 independent · 26 company-owned · 1 unclear

Evidence support

46 direct · 7 partial

Keep in mind

Use the run research_date as the study date. Platform-reported dates are provenance metadata and do not independently prove freshness.

Technical verification details

Use this SHA-256 fingerprint to identify the source snapshot associated with this study.

7ef90d809f4c1d74edc142599112b6fb63cf861959abdba308b836d27c43efb0